Effects of Interleukin-1 Beta on Ovarian Cancer in Mice
Author Information
Author(s): Saleem T.A. Malik, N. East, D. Boraschi, F.R. Balkwill
Primary Institution: Biological Therapies Laboratory, Imperial Cancer Research Fund
Hypothesis
How does intraperitoneal recombinant interleukin-1 beta affect human ovarian cancer xenograft models?
Conclusion
Intraperitoneal administration of interleukin-1 beta can lead to both tumor implantation and antitumor effects depending on the dose and the specific xenograft model.
Supporting Evidence
- Interleukin-1 beta administration led to solid tumor formation in two out of three xenograft models.
- Low doses of interleukin-1 beta promoted micrometastatic peritoneal implants in one model.
- High doses of interleukin-1 beta showed marked antitumor effects in another model.
Takeaway
This study shows that a substance called interleukin-1 beta can help fight cancer in mice, but it can also make some tumors grow more.
Methodology
The study used three different human ovarian cancer xenograft models in nude mice, administering interleukin-1 beta and measuring effects on tumor growth and survival.
Limitations
The study was conducted in mice, which may not fully replicate human responses.
Participant Demographics
Nude mice aged 6 to 12 weeks, mixed genetic background.
Statistical Information
P-Value
p<0.005
Statistical Significance
p<0.005
Want to read the original?
Access the complete publication on the publisher's website